ACHN Volume Alert - ACHN 12.85 Achillion Pharmaceu
Post# of 94145
Posted On: 11/11/2014 11:45:59 AM
ACHN Volume Alert - ACHN 12.85 Achillion Pharmaceuticals $ACHN Hit a high of 13.38 Currently 11:15 Last price 12.85 unch unch With a day low of 12.22 and a current volume of 7,590,134.
ACHN Achillion Pharmaceuticals Recent Headline News
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - 32 mins ago
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), MRK: 59.50 (+0.69), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - 42 mins ago
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - 1 hr 37 mins ago
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - 2 hrs 7 mins ago
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - 2 hrs 14 mins ago
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 15.84 (+0.98), AMD: 2.73 (-0.03), ACHN: 12.73 (-0.12), CLDX: 14.72 (-0.09), ILMN: 187.87 (-0.40)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - 2 hrs 39 mins ago
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 16.09 (-0.31), ACHN: 12.73 (-0.12), ILMN: 187.87 (-0.40), AFFX: 9.41 (-0.01)
Most active Nasdaq-traded stocks
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
ACHN: 12.73 (-0.12), DNDN: 0.18 (unch), CMCSK: 51.83 (-1.00), ARCP: 8.63 (+0.13), MSFT: 48.86 (-0.03), INTC: 33.44 (+0.18), CMCSA: 52.00 (-0.95), AAPL: 108.85 (+0.02), CSCO: 25.19 (+0.04)
Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.08 (-0.05), PCMI: 8.60 (-0.20), ACHN: 12.73 (-0.12), TGTX: 13.00 (+0.45), AGIO: 84.61 (+2.83), LIOX: 5.31 (-0.23), PLNR: 7.14 (-0.54)
Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 11.70 (-0.19), JRJC: 7.74 (+1.30), NAVB: 1.00 (-0.03), SANW: 3.60 (-0.04), PLPM: 1.70 (+0.03), RYN: 26.68 (-2.14), INFU: 2.85 (-0.12), LIOX: 5.31 (-0.23), DY: 27.66 (-0.31), MTZ: 24.21 (-0.72), CGIX: 6.49 (-0.19), MUX: 1.32 (+0.09), OREX: 5.08 (-0.05), URRE: 2.43 (-0.13), ACHN: 12.73 (-0.12), REN: 2.60 (-0.30), MPO: 3.14 (-0.07), AKBA: 9.71 (+0.72), TRX: 1.09 (+0.05), PLNR: 7.14 (-0.54)
Achillion up on HCV data
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:30AM CST
ACHN: 12.73 (-0.12)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), MRK: 59.50 (+0.69), ABBV: 64.00 (+0.21), BMY: 59.12 (+0.31)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), RGLS: 20.46 (-0.45), ABBV: 64.00 (+0.21)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST
PT: 1.76 (+0.12), GPRO: 75.40 (-0.35), OREX: 5.08 (-0.05), GOGO: 17.81 (-0.59), JRJC: 7.74 (+1.30), UEC: 1.84 (-0.06), ACHN: 12.73 (-0.12), ARQL: 1.17 (unch), CMCM: 19.17 (-1.39), IBIO: 1.17 (-0.06), DF: 16.09 (-0.31)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 64.00 (+0.21), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -
ACHN: 12.73 (-0.12)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.73 (-0.12)
ACHN Achillion Pharmaceuticals Recent Headline News
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - 32 mins ago
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), MRK: 59.50 (+0.69), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - 42 mins ago
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - 1 hr 37 mins ago
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - 2 hrs 7 mins ago
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - 2 hrs 14 mins ago
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 15.84 (+0.98), AMD: 2.73 (-0.03), ACHN: 12.73 (-0.12), CLDX: 14.72 (-0.09), ILMN: 187.87 (-0.40)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - 2 hrs 39 mins ago
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 63.99 (+0.20), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 16.09 (-0.31), ACHN: 12.73 (-0.12), ILMN: 187.87 (-0.40), AFFX: 9.41 (-0.01)
Most active Nasdaq-traded stocks
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
ACHN: 12.73 (-0.12), DNDN: 0.18 (unch), CMCSK: 51.83 (-1.00), ARCP: 8.63 (+0.13), MSFT: 48.86 (-0.03), INTC: 33.44 (+0.18), CMCSA: 52.00 (-0.95), AAPL: 108.85 (+0.02), CSCO: 25.19 (+0.04)
Nasdaq stocks posting largest percentage increases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
OREX: 5.08 (-0.05), PCMI: 8.60 (-0.20), ACHN: 12.73 (-0.12), TGTX: 13.00 (+0.45), AGIO: 84.61 (+2.83), LIOX: 5.31 (-0.23), PLNR: 7.14 (-0.54)
Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 11.70 (-0.19), JRJC: 7.74 (+1.30), NAVB: 1.00 (-0.03), SANW: 3.60 (-0.04), PLPM: 1.70 (+0.03), RYN: 26.68 (-2.14), INFU: 2.85 (-0.12), LIOX: 5.31 (-0.23), DY: 27.66 (-0.31), MTZ: 24.21 (-0.72), CGIX: 6.49 (-0.19), MUX: 1.32 (+0.09), OREX: 5.08 (-0.05), URRE: 2.43 (-0.13), ACHN: 12.73 (-0.12), REN: 2.60 (-0.30), MPO: 3.14 (-0.07), AKBA: 9.71 (+0.72), TRX: 1.09 (+0.05), PLNR: 7.14 (-0.54)
Achillion up on HCV data
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 10:30AM CST
ACHN: 12.73 (-0.12)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), MRK: 59.50 (+0.69), ABBV: 64.00 (+0.21), BMY: 59.12 (+0.31)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), RGLS: 20.46 (-0.45), ABBV: 64.00 (+0.21)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:14AM CST
PT: 1.76 (+0.12), GPRO: 75.40 (-0.35), OREX: 5.08 (-0.05), GOGO: 17.81 (-0.59), JRJC: 7.74 (+1.30), UEC: 1.84 (-0.06), ACHN: 12.73 (-0.12), ARQL: 1.17 (unch), CMCM: 19.17 (-1.39), IBIO: 1.17 (-0.06), DF: 16.09 (-0.31)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 109.26 (+0.44), GILD: 108.59 (+1.57), ACHN: 12.73 (-0.12), CNAT: 7.00 (-0.06), MRK: 59.50 (+0.69), LGND: 57.61 (+1.93), RGLS: 20.46 (-0.45), ABBV: 64.00 (+0.21), BMY: 59.12 (+0.31), ENTA: 44.06 (-0.08)
Achillion Reports 100% SVR12 in a Phase 2 Combination Study With ACH-3102 at the Liver Meeting 2014 (AASLD)
GlobeNewswire - Sat Nov 08, 8:01AM CST
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"
Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline - ACHN: 12.73 (-0.12)
Achillion Announces Upcoming Poster Presentations Discussing Novel Oral Complement Factor D Inhibitor Platform at the 56th Annual Meeting of the American Society of Hematology
GlobeNewswire - Thu Nov 06, 8:45AM CST
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56 Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/.
ACHN: 12.73 (-0.12)
(0)
(0)Scroll down for more posts ▼